To improve the lives of patients by creating & developing innovative antibody products

Genmab

Approved Partnered Products
Solid Financial Base

DARZALEX® (daratumumab)[1],
Arzerra® (ofatumumab)[2],
TEPEZZA™ (teprotumumab)[3]

Our Own Clinical Pipeline
Potential first-in-class / Best-in-class

Tisotumab vedotin[4], enapotamab vedotin, HexaBody®-DR5/DR5, epcoritamab (DuoBody®-CD3xCD20), DuoBody-PD-L1x4-1BB (GEN1046)[5], DuoBody-CD40x4-1BB (GEN1042)[5] & DuoHexaBody®-CD37 (GEN309)[6]

Partner Programs in the Clinic
Programs Built on Genmab's Innovation

11 in clinical development with partners with royalty streams for Genmab should they come to market.
Includes 6 DuoBody products with Janssen; Ofatumumab[7] (RMS)

Technologies & Preclinical
R&D Engine: Powerhouse of Innovation

DuoBody tech., HexaBody tech., DuoHexaBody tech., HexElect® tech. & Rich preclinical pipeline incl. HexaBody-CD38 (GEN3014)[8] & DuoBody-CD3x5T4 (GEN1044)

Our Three-pronged Strategy

- Focus on core competence
- Turn science into medicine
- Build a profitable & successful biotech

Our Vision

By 2025, our own product has transformed cancer treatment and we have a pipeline of knock-your-socks-off antibodies

Proprietary technologies allow us to build a world-class pipeline

Match in-house expertise with strategic partnerships → Strong pipeline of first-in-class / best-in-class products

Deep insight into antibody biology & disease targets

2020 Guidance

Income Statement	DKKM	USDM[9]
Revenue	4,750 – 5,150	731 - 792
Operating expenses	(3,850) – (3,950)	(592) – (608)
Operating income	850 – 1,250	131 - 192

[9]USD 1.00 = DKK 6.50

DKK
96B
~USD 14B[10]
2019 year-end market cap

DKK
2,728M
~USD 408M[10]
2019 operating expenses
87% invested in R&D

[10]USD 1.00 = DKK 6.6759

DKK
5,366M
~USD 803M[10]
2019 revenue
77% increase vs 2018

DKK
10,971M
~USD 1,643M[10]
2019 year end cash position

Revenue
MDDK
(~MUSD[10])



For more information/contact: genmab.com/ir@genmab.com

[1]In dev. by Janssen; [2]with Novartis; [3]In dev. by Horizon; [4]50:50 w/ Seattle Genetics; [5]50:50 w/ BioNTech; [6]IND submitted Q4 2019 [7]In dev. by Novartis [8]Genmab is developing HexaBody-CD38 in an exclusive worldwide license and option agreement with Janssen Biotech, Inc

Mar 1, 2020

Innovation Powerhouse

Genmab Proprietary[11] Product Candidates

Product	Target	Rights	Indications	Most Advanced Dev. Phase (Pre-clin. / I / I/II / II / III / Appr.)
Tisotumab vedotin	TF	50:50 Genmab / Seattle Genetics	Cervical cancer	II
			Ovarian cancer	II
			Solid tumors	II
Enapotamab vedotin	AXL	Genmab	Solid tumors	I/II
HexaBody-DR5/DR5	DR5	Genmab	Solid tumors	I
Epcoritamab	CD3, CD20	Genmab	Hem. malig.	I
DuoBody-PD-L1x4-1BB	PD-L1, 4-1BB	50:50 Genmab / BioNTech	Solid tumors	I
DuoBody-CD40x4-1BB	CD40, 4-1BB	50:50 Genmab / BioNTech	Solid tumors	I
In the clinic in 2020 DuoHexaBody-CD37	CD37	Genmab	Hem. malig.	Pre-clin.
IND/CTAs in 2020 DuoBody-CD3x5T4 & HexaBody-CD38[12]				Pre-clin.
Approved Products in Collaboration, Including Any Proposed Label Expansions				
Daratumumab	CD38	Janssen[13]	MM	Appr.
			AL Amyloidosis	III
			Non-MM blood cancers	II
Ofatumumab	CD20	Novartis[13,14]	CLL	Appr.
Teprotumumab	IGF-1R	Horizon[13]	TED	Appr.
Pipeline Products in Collaboration				
Ofatumumab (OMB157)	CD20	Novartis	RMS	II
Camidanlumab tesirine	CD25	ADC Therapeutics	R/R Hodgkin lymphoma	II
			Solid tumors	I
Mim8	FIX(a), FX	Novo Nordisk	Hemophilia A	I/II
Humax-IL8	IL8	BMS	Advanced cancers	I/II
JNJ-61186372	EGFR, cMet	Janssen	NSCLC	I/II
JNJ-63709178	CD123, CD3	Janssen	AML	I
JNJ-64007957	BCMA, CD3	Janssen	R/R MM	I
JNJ-64407564	GPRC5D, CD3	Janssen	R/R MM	I
JNJ-67571244	CD33, CD3	Janssen	R/R AML or MDS	I
JNJ-63898081	PSMA, CD3	Janssen	Solid tumors	I
Lu AF82422	α synuclein	Lundbeck	Parkinson's	I
~20 active pre-clinical programs	Partnered & proprietary programs: HuMab, DuoBody, DuoHexaBody and HexaBody			Pre-clin.

Products & Technologies

Tisotumab vedotin
- Antibody-drug conjugate (ADC) in development to treat solid tumors
- Ph. II potential reg. study in cervical cancer
- Ph II studies in ovarian & other solid tumors
- 50:50 agreement w/ Seattle Genetics

Enapotamab vedotin
- ADC in development to treat solid tumors
- Ph I/II trial for multiple solid tumors

HexaBody-DR5/DR5 (GEN1029)
- Proprietary antibody therapeutic created with Genmab's HexaBody technology
- Phase I/II trial in solid tumors

Epcoritamab (DuoBody-CD3xCD20)
- Proprietary bispecific antibody created with Genmab's DuoBody technology
- Phase I/II trial in B-cell malignancies

DuoBody-PD-L1x4-1BB (GEN1046)
- Bispecific antibody created w/ DuoBody tech
- Phase I/II trial in solid tumors
- 50:50 agreement w/ BioNTech

DuoBody-CD40x4-1BB (GEN1042)
- Bispecific antibody created w/ DuoBody tech
- Phase I/II trial in solid tumors
- 50:50 agreement w/ BioNTech

DuoHexaBody-CD37 (GEN3009)
- Based on combination of DuoBody & HexaBody platforms
- IND filed in 2019

Ofatumumab (OMB157)
- SubQ formulation in dev. with Novartis to treat relapsing multiple sclerosis (RMS)
- Regulatory submissions made to US & EU authorities for ofatumumab in RMS

DARZALEX (daratumumab)
- First-in-class CD38 antibody
- Approved in certain territories for various multiple myeloma (MM) indications[13]
- Regulatory submissions for SubQ formulation in 2019
- Collaboration w/ Janssen
- 2019 net sales by Janssen: $2,998M, DKK 3,132M royalties to Genmab

TEPEZZA (teprotumumab)
- Developed & manufactured by Horizon Therapeutics
- Approved in US for thyroid eye disease[13]
- Created under collaboration with Roche
- Under terms of agreement with Roche, Genmab to receive mid-single digit royalties on sales

DuoBody Platform
- Bispecific antibody technology platform
- Potential in cancer, autoimmune, infectious, cardiovascular, central nervous system diseases & hemophilia
- Multiple commercial & research collaborations

HexaBody Platform
- Enhanced potency antibody technology platform
- Broadly applicable technology that builds on natural antibody biology

DuoHexaBody Platform
- Antibody technology that combines
- DuoBody & HexaBody platforms
- Creates bispecific antibodies with target-mediated enhanced potency

HexElect Platform
- Antibody technology platform inspired by HexaBody platform
- Combines dual targeting with enhanced selectivity & potency

Founded: 1999
Exchanges: CSE / Nasdaq
Symbol: GMAB
Shares outstanding: 65,156,578
Market Cap as of February 19, 2020: DKK 106B (USD 15,427M)

Executive Management:
Jan G. J. van de Winkel, Ph.D., President & CEO
Anthony Pagano, EVP & CFO
Judith Klimovsky M.D., EVP & CDO

[11]Certain product candidates in development with partners, as noted
[12]Genmab is developing HexaBody-CD38 in an exclusive worldwide license and option agreement with Janssen Biotech, Inc.
[13]See local country prescribing information for precise indications
[14]Not in active development. Jan. 22, 2018: Novartis announced intention to transition Arzerra from commercially available to limited availability via compassionate use programs in non-US markets.